SEC Info - Rite Aid Corp. - ‘10-Q’ for 5/28/22

SEC Info℠

Home

My Interests

Help

Please Sign In

Rite Aid Corp. – ‘10-Q’ for 5/28/22 – ‘EX-10.36’

On: Wednesday, 7/6/22, at 11:47am ET · For: 5/28/22 · Accession #: 1558370-22-10556 · File #: 1-05742

Previous ‘10-Q’: ‘10-Q’ on 1/5/22 for 11/27/21 · Next: ‘10-Q’ on 10/5/22 for 8/27/22 · Latest: ‘10-Q’ on 10/18/23 for 9/2/23 · 36 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/06/22  Rite Aid Corp.                    10-Q        5/28/22   88:10M                                    Toppan Merrill Bridge/FA

Quarterly Report — Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.19M 
 2: EX-4.10     Instrument Defining the Rights of Security Holders  HTML     35K 
 3: EX-4.11     Instrument Defining the Rights of Security Holders  HTML     35K 
 4: EX-10.35    Material Contract                                   HTML     57K 
 5: EX-10.36    Material Contract                                   HTML     59K 
 6: EX-22       Published Report re: Matters Submitted to a Vote    HTML     39K 
                of Security Holders                                              
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 9: EX-32       Certification -- §906 - SOA'02                      HTML     26K 
15: R1          Document and Entity Information                     HTML     76K 
16: R2          Condensed Consolidated Balance Sheets               HTML    127K 
17: R3          Condensed Consolidated Balance Sheets               HTML     34K 
                (Parenthetical)                                                  
18: R4          Condensed Consolidated Statements of Operations     HTML    110K 
19: R5          Condensed Consolidated Statements of Comprehensive  HTML     49K 
                Loss                                                             
20: R6          Condensed Consolidated Statements of Comprehensive  HTML     26K 
                Loss (Parenthetical)                                             
21: R7          Condensed Consolidated Statements of Stockholders'  HTML     85K 
                Equity                                                           
22: R8          Condensed Consolidated Statements of Stockholders'  HTML     26K 
                Equity (Parenthetical)                                           
23: R9          Condensed Consolidated Statements of Cash Flows     HTML    113K 
24: R10         Basis of Presentation and Significant Accounting    HTML     48K 
                Policies                                                         
25: R11         Acquisition                                         HTML     56K 
26: R12         Restructuring                                       HTML     88K 
27: R13         Income (Loss) Per Share                             HTML     47K 
28: R14         Facility Exit and Impairment Charges                HTML    114K 
29: R15         Fair Value Measurements                             HTML     29K 
30: R16         Income Taxes                                        HTML     30K 
31: R17         Medicare Part D                                     HTML     33K 
32: R18         Manufacturer Rebates Receivables                    HTML     25K 
33: R19         Goodwill and Other Intangible Assets                HTML    116K 
34: R20         Indebtedness and Credit Agreements                  HTML     74K 
35: R21         Leases                                              HTML    135K 
36: R22         Retirement Plans                                    HTML     47K 
37: R23         Segment Reporting                                   HTML    139K 
38: R24         Commitments, Contingencies and Guarantees           HTML     45K 
39: R25         Supplementary Cash Flow Data                        HTML     40K 
40: R26         Basis of Presentation and Significant Accounting    HTML     53K 
                Policies (Policies)                                              
41: R27         Basis of Presentation and Significant Accounting    HTML     41K 
                Policies (Tables)                                                
42: R28         Acquisition (Tables)                                HTML     54K 
43: R29         Restructuring (Tables)                              HTML     86K 
44: R30         Income (Loss) Per Share (Tables)                    HTML     45K 
45: R31         Facility Exit and Impairment Charges (Tables)       HTML    110K 
46: R32         Goodwill and Other Intangible Assets (Tables)       HTML    204K 
47: R33         Indebtedness and Credit Agreements (Tables)         HTML     54K 
48: R34         Leases (Tables)                                     HTML    170K 
49: R35         Retirement Plans (Tables)                           HTML     43K 
50: R36         Segment Reporting (Tables)                          HTML    138K 
51: R37         Supplementary Cash Flow Data (Tables)               HTML     39K 
52: R38         Basis of Presentation and Significant Accounting    HTML     49K 
                Policies - Sales (Details)                                       
53: R39         Basis of Presentation and Significant Accounting    HTML     49K 
                Policies - FY thru Revenue (Details)                             
54: R40         Acquisition (Details)                               HTML     32K 
55: R41         Acquisition - Purchase price allocation (Details)   HTML     80K 
56: R42         Acquisition - Intangible assets acquired (Details)  HTML     33K 
57: R43         Acquisition - Acquisition costs (Details)           HTML     34K 
58: R44         Restructuring (Details)                             HTML     62K 
59: R45         Income (Loss) Per Share (Details)                   HTML     60K 
60: R46         Facility Exit and Impairment Charges (Details)      HTML     41K 
61: R47         Facility Exit and Impairment Charges - Fair value   HTML     38K 
                (Details)                                                        
62: R48         Facility Exit and Impairment Charges - Closed       HTML     48K 
                Store Liability rollforward (Details)                            
63: R49         Fair Value Measurements (Details)                   HTML     33K 
64: R50         Income Taxes (Details)                              HTML     36K 
65: R51         Medicare Part D (Details)                           HTML     53K 
66: R52         Manufacturer Rebates Receivables (Details)          HTML     30K 
67: R53         Goodwill and Other Intangibles - Goodwill           HTML     35K 
                (Details)                                                        
68: R54         Goodwill and Other Intangible Assets - Intangibles  HTML     69K 
                (Details)                                                        
69: R55         Goodwill and Other Intangible Assets - Unfavorable  HTML     39K 
                lease intangibles and amortization expense                       
                (Details)                                                        
70: R56         Indebtedness and Credit Agreements - Indebtedness   HTML     77K 
                and lease financing obligations (Details)                        
71: R57         Indebtedness and Credit Agreement - Credit          HTML    107K 
                Facility (Details)                                               
72: R58         Indebtedness and Credit Agreement - Transactions    HTML     90K 
                and Maturity (Details)                                           
73: R59         Leases (Details)                                    HTML     55K 
74: R60         Leases - Supplemental cash flow information         HTML     36K 
                related to leases (Details)                                      
75: R61         Leases - Supplemental BS Information (Details)      HTML     59K 
76: R62         Leases - Maturity of lease liabilities under        HTML     85K 
                finance and operating leases (Details)                           
77: R63         Leases - Sale Leaseback (Details)                   HTML     30K 
78: R64         Retirement Plans - Benefit obligation and funded    HTML     58K 
                status (Details)                                                 
79: R65         Segment Reporting - Balance Sheet information       HTML     50K 
                (Details)                                                        
80: R66         Segment Reporting - Revenues (Details)              HTML     55K 
81: R67         Segment Reporting - Adjusted EBITDA (Details)       HTML     66K 
82: R68         Commitments, Contingencies and Guarantees           HTML     45K 
                (Details)                                                        
83: R69         Supplementary Cash Flow Data (Details)              HTML     38K 
86: XML         IDEA XML File -- Filing Summary                      XML    153K 
84: XML         XBRL Instance -- rad-20220528x10q_htm                XML   2.45M 
85: EXCEL       IDEA Workbook of Financial Reports                  XLSX    111K 
11: EX-101.CAL  XBRL Calculations -- rad-20220528_cal                XML    238K 
12: EX-101.DEF  XBRL Definitions -- rad-20220528_def                 XML    663K 
13: EX-101.LAB  XBRL Labels -- rad-20220528_lab                      XML   1.41M 
14: EX-101.PRE  XBRL Presentations -- rad-20220528_pre               XML   1.02M 
10: EX-101.SCH  XBRL Schema -- rad-20220528                          XSD    192K 
87: JSON        XBRL Instance as JSON Data -- MetaLinks              422±   611K 
88: ZIP         XBRL Zipped Folder -- 0001558370-22-010556-xbrl      Zip    294K

‘EX-10.36’ — Material Contract

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

C: C: <! <>

Exhibit 10.36

March 7, 2022

James Peters

Rite Aid Corporation

30 Hunter Lane

Camp Hill, PA 17011

Re:Separation of Employment

Dear Jim:

This letter agreement (this “Agreement”) confirms our understanding and agreement with respect to your separation of employment with Rite Aid Corporation (the “Company,” each a “Party” and together with you, the “Parties”). Capitalized terms not otherwise defined herein will have the meanings attributed to them in the employment agreement by and between you and the Company dated October 2, 2019 (the “Employment Agreement”).

1.Separation of Employment. Your last day of employment with the Company is March 7, 2022 (the “Separation Date”). As of the Separation Date, you irrevocably resign from all positions you currently hold with the Company and its subsidiaries, including as Chief Operating Officer, and you agree to execute the resignation letter attached hereto as Appendix A. You agree that, following the Separation Date, you will not represent yourself to be associated in any capacity with the Company or any of its subsidiaries or affiliates.

2.Accrued Benefits; Severance.

(a)Whether or not this Agreement becomes effective pursuant to its terms, the Company will pay you the Accrued Benefits (as defined in Appendix B hereto), and pay in lieu of notice, as set forth in item 2(g) of Appendix B hereto, less all applicable withholdings and deductions.

(b)Provided that this Agreement becomes effective on the Release Effective Date (as defined in Section 5(c) below) and you remain in compliance in all material respects with this Agreement, the Company will pay you the severance amount and fulfill the obligations set forth on Appendix B items 2(a) through 2(f), less all applicable withholdings and deductions, at the time and in the form set forth on Appendix B for each item (the “Release Consideration”).

3.Release.

(a)You hereby release, discharge and forever acquit the Company, and its affiliates and subsidiaries and each of their past, present and future stockholders, directors, employees, agents, successors and assigns of the foregoing, in their personal and representative capacities (individually, “Company Party,” and collectively, the “Company Parties”), from liability for, and hereby waive, any and all claims, charges, liabilities, causes of action, rights, complaints, sums of money, suits, debts, covenants, contracts, agreements, promises, benefits, obligations, damages, demands or liabilities of every nature, kind and description, in law, equity or otherwise, whether known or unknown, suspected or unsuspected (collectively, “Claims”) which you or your heirs, executors, administrators, spouse, relatives, successors or assigns ever had, now have or may hereafter claim to have by reason of any matter, cause or thing whatsoever: (i) arising from the beginning of time through the date upon which you execute this Agreement

including, but not limited to (A) any such Claims relating in any way to your employment relationship with the Company or any other Company Parties, and (B) any such Claims arising under any federal, state, local or foreign statute or regulation, including, without limitation, the Age Discrimination in Employment Act of 1967, as amended by the Older Workers Benefit Protection Act (the “ADEA”), Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, the Employee Retirement Income Security Act of 1974, the Pennsylvania Human Relations Act, the Pennsylvania Equal Pay Law and any other federal, state, local or foreign law (statutory, regulatory or otherwise) that may be legally waived and released; (ii) relating to wrongful employment termination; or (iii) arising under or relating to any policy, agreement, understanding or promise, written or oral, formal or informal, between the Company or any of the other Company Parties and you, including, without limitation, the Employment Agreement and any incentive compensation plan or equity plan with any Company Party. Notwithstanding the above, this release does not extend to (A) claims for Accrued Benefits; (B) claims for worker’s compensation benefits or for an occupational disease; (C) any whistleblower claims arising under the Sarbanes-Oxley Act or Dodd-Frank Wall Street Reform and Consumer Protection Act; (D) claims to require the Company to honor its commitments set forth in this Agreement; (E) claims for indemnification and officers and directors liability insurance coverage under Section 4.6 of the Employment Agreement, the Company’s charter, by-laws or applicable law; and/or (F) claims that cannot be waived as a matter of law pursuant to federal, state, or local law (collectively, clauses (A) through (F) are the “Excluded Claims”).

(b)You further acknowledge and agree that, except with respect to the Accrued Benefits, the Company Parties have fully satisfied any and all obligations whatsoever owed to you arising out of your employment with the Company or any other Company Party, and that no further payments or benefits are owed to you by the Company or any other Company Party except as provided for in this Agreement.

4.Attorney Consultation; Voluntary Agreement. You acknowledge that (a) the Company has advised you to consult with an attorney of your own choosing before signing this Agreement, (b) you have been given the opportunity to seek the advice of counsel, (c) you have carefully read and fully understand all of the provisions of this Agreement, including the release in Section 3 (the “Release”), (d) the Release specifically applies to any rights or claims you may have against the Company Parties pursuant to the ADEA, (e) you are entering into this Agreement knowingly, freely and voluntarily in exchange for good and valuable consideration to which you are not otherwise entitled, including the payments and benefits referenced in items 2(a) through 2(f) of Appendix B of this Agreement and (f) you have the full power, capacity and authority to enter into this Agreement.

5.Review and Revocation Period.

(a)You have forty-five days following your receipt of this Agreement to review its terms, including the Release, and to reflect upon them and consider whether you want to sign it, although you may sign it sooner; provided, however, that you may not sign this Agreement prior to the Separation Date. You acknowledge and agree that changes to this Agreement (including Appendix B), whether material or immaterial, do not restart the running of this forty-five day period. You understand and agree that you may consent to this Agreement, including the Release, by signing and returning this Agreement within the applicable time frame to the CHRO (as defined on Appendix B).

(b)You may revoke your consent to the Release within the seven day period beginning on the date you execute this Agreement (such seven day period being referred to herein as the “Release Revocation Period”). To be effective, such revocation must be in writing signed by you and delivered to the Company at the above address before 11:59 p.m., Eastern Standard time, on the last day of the Release Revocation Period.

(c)In the event of such revocation by you, the Release shall be of no force or effect, and you will not have any rights and the Company will not have any obligations under Section 2(b) of this Agreement. Provided that you do not revoke your consent to the Release within the Release Revocation Period, the Release shall become effective on the eighth (8th) calendar day after the date upon which you execute this Agreement (the “Release Effective Date”).

6.Restrictive Covenants. You acknowledge and agree that the confidentiality obligations and the restrictive covenants and agreements set forth in Sections 6 and 7 of the Employment Agreement, respectively, and any other written restrictive covenants and confidentiality agreements in effect with the Company, are incorporated herein by reference and fully made a part hereof for all purposes and remain in full force and effect. You agree to keep the contents of this Agreement strictly confidential except as necessary to obtain the advice of your tax and legal advisors.

7.Cooperation. You agree that, at mutually agreeable times, you will meet with representatives of the Company, or its respective parent or subsidiary company representatives and provide any information you acquired during the course of your employment relating in any way to any legal disputes involving the Company. You further agree that you will cooperate fully with the Company relating to any such litigation matter or other legal proceeding in which you were involved or on which you have knowledge by virtue of your employment with the Company, including any existing or future litigation or other legal proceeding involving the Company, whether administrative, civil or criminal in nature in which and to the extent the Company deems your cooperation necessary. You will be entitled to reimbursement by the Company of reasonable costs and expenses incurred by you in connection with complying with your obligations under Section 7 of this Agreement.

8.Non-Disparagement. You agree that you will not make any negative comments or disparaging remarks, in writing, orally or electronically (“Disparaging Remarks”), about the Company or any of the other Company Parties and their respective products and services. The Company agrees to instruct members of its senior management team not to, for as long as such individuals remain affiliated with the Company, make any Disparaging Remarks about you; provided, however, that nothing in this Section 8 shall prohibit you from (a) making truthful and accurate statements or disclosures that are required by applicable law or legal process; (b) making any voluntary disclosure of information or documents concerning possible violations of law to any governmental agency or legislative body, or any self-regulatory organization; or (c) exercising protected rights to the extent that such rights, by law, cannot be waived by agreement.

9.Permitted Disclosures. Pursuant to 18 U.S.C. § 1833(b), you will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret of the Company that (a) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to your attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney and use the trade secret information in the court proceeding if you (I) file any document containing the trade secret under seal and (II) do not disclose the trade secret except pursuant to court order. Nothing in this Agreement or any other agreement you have with the Company is intended to conflict with 18 U.S.C. § 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such section. Further, nothing in any agreement you have with the Company will prohibit or restrict you from making any voluntary disclosure of information or documents related to any violation of law to any governmental agency or legislative body, or any self-regulatory organization, in each case, without advance notice to the Company.

10.No Admission. Nothing herein will be deemed to constitute an admission of wrongdoing by you or any of the Company Parties. Neither this Agreement nor any of its terms may be used as an admission or introduced as evidence as to any issue of law or fact in any proceeding, suit or action, other than an action to enforce this Agreement. Notwithstanding the foregoing, Parties acknowledge that the separation of employment is not a Termination of Executive’s Employment by the Company for Cause as reflected in Section 5.1 of Employment Agreement.

11.Counterparts. This Agreement may be executed in counterparts, and each counterpart, when so executed and delivered, will be deemed to be an original and both counterparts, taken together, will constitute one and the same Agreement. A faxed, .pdf-ed or other e-sign signature such as through DocuSign will operate the same as an original signature.

12.Successors and Assigns. This Agreement will inure to the benefit of and be binding upon the Company and any successor organization which shall succeed to the Company by acquisition, merger, consolidation or operation of law, or by acquisition of assets of the Company and any assigns. You may not assign this Agreement, except with respect to the rights provided under Section 2 of this Agreement, which will inure to the benefit of your heirs, executors and administrators. In the event of your death at any time, your estate will receive all unpaid payments and benefits due you under this Agreement, including under Appendix B.

13.Severability; Blue-Penciling. The provisions of this Agreement are severable and the invalidity of any one or more provisions will not affect the validity of any other provision. In the event that a court of competent jurisdiction shall determine that any provision of this Agreement or the application thereof is unenforceable in whole or in part because of the scope thereof, the Parties hereto agree that said court in making such determination shall have the power to reduce the scope of such provision to the extent necessary to make it enforceable, and that this Agreement in its reduced form shall be valid and enforceable to the full extent permitted by law.

14.Governing Law. This Agreement will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to any conflict of law principles thereof that would give rise to the application of the laws of any other jurisdiction.

15.Entire Agreement/No Oral Modifications. This Agreement including Appendix B constitutes the entire agreement between you and any of the Company Parties with respect to the subject matter hereof and supersedes all prior discussions, negotiations, representations, arrangements or agreements relating thereto, whether written or oral, including but not limited to the Employment Agreement, provided, however, that (i) Section 4.6 of the Employment Agreement shall survive the Separation Date, (ii) Sections 6 and 7 of the Employment Agreement shall remain in effect, for the duration and on the terms set forth therein, and (iii) any other defined terms contained in the Employment Agreement shall not be superseded hereby to the extent necessary for the interpretation, application, or enforcement of this Agreement. You represent that in executing this Agreement, you have not relied on any representation or statement not set forth herein. No amendment or modification of this Agreement shall be valid or binding on the Parties unless in writing and signed by both Parties.

***

IN WITNESS WHEREOF, the Parties have signed this Agreement as of the dates indicated below.

Rite Aid Corporation	James Peters


By: /s/ *Paul Gilbert*_______ Paul Gilbert EVP, Secretary and General Counsel Date: April 13, 2022	__/s/ *James Peters*__________________ James Peters Date: April 13, 2022

A[Do not delete - this paragraph generates the automatic page number]

APPENDIX A

March 7, 2022
Rite Aid Corporation
30 Hunter Lane
Camp Hill, PA 17011

To Whom it may Concern:

I hereby irrevocably resign, effective as of March 7, 2022, from all positions and offices I hold with the Company and its subsidiaries, including as Chief Operating Officer.

Very truly yours,

/s/ James Peters
_________________
James Peters

APPENDIX B

ACCRUED BENEFITS AND SEVERANCE BENEFITS

The term “CHRO” means and refers to Jessica Kazmaier, Executive Vice President and Chief Human Resources Officer, Rite Aid Corporation, 30 Hunter Lane, Camp Hill, PA 17011 or by e-mail at jkazmaier@riteaid.com.

Accrued Benefits: The Company will pay you (i) your Base Salary earned through the Separation Date; (ii) any reimbursements owed to you pursuant to Section 4.2 of the Employment Agreement for expenses incurred prior to the Separation Date; and (iii) the amounts accrued and credited to your account under the Company’s 401(k) Savings Plan, and other applicable tax-qualified retirements plans in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (the “Accrued Benefits”). You acknowledge that there is no accrued or unpaid vacation payable to you under the Company’s unlimited paid time off policy.

Severance Benefits: You will be paid or provided with the following payments/benefits:

$3,712,500 representing two (2) times the sum of your current Base Salary and Annual Target Bonus, payable in equal installments over the two year period following the Release Effective Date in accordance with the Company’s regular payroll practices, commencing with the first regular payroll date that occurs after the Release Effective Date. Notwithstanding the foregoing, to the extent necessary to avoid adverse tax consequences, and except as described below, any payment to which you become entitled under the Agreement, or any arrangement or plan referenced in this Agreement, that constitutes “deferred compensation” under Internal Revenue Code Section 409A (“409A”), and is (a) payable upon your termination of employment; (b) at a time when you are a “specified employee” as defined by 409A shall not be made until the first payroll date after the earliest of: (1) the expiration of the six (6) month period (the “Deferral Period”) measured from the date of your “separation from service” within the meaning of such term under 409A; or (2) your date of death following such separation from service. Upon the expiration of the Deferral Period, any payments that would have otherwise been made during that period (whether in a single sum or in installments) will be paid in a single cash lump sum payment to you (or your beneficiary, as applicable). Each installment or amount to be paid or benefit to be provided to you will be construed as a “separate identified payment” for purposes of 409A to the fullest extent permitted therein.

Payment of your annual bonus for FY 2022 based on actual performance following determination by the Compensation Committee (or the Board) that the Company has achieved or exceeded its annual performance targets for the fiscal year, paid at the same time as annual performance bonus amounts are paid to the Company’s similarly situated active associates generally in respect of FY 2022.

Payment of a pro rata portion of your annual bonus for FY 2023 at the same time as is paid to other eligible participants in the bonus plan, following determination by the Compensation Committee (or the Board) of the Company’s performance under the applicable annual performance goals for the fiscal year, determined by multiplying the performance level achieved (relative to Executive’s Annual Target Bonus amount) by a

fraction (x) the numerator of which is the number of fiscal periods (months) in which Executive is employed (in this case, this amounts to 9/30 months, or 0.3 months, and (y) the denominator of which is 12, which would result in the payment of $25,781.25 at target), paid at the same time as annual performance bonus amounts are paid to the Company's executive team in respect of FY 2023.

Accelerated vesting as of the Release Effective Date with respect to those stock options and time-based restricted stock awards that would have vested within the two (2) year period following the Separation Date; any vested stock options shall remain exercisable for a period of ninety (90) days following the Separation Date. E*Trade will be instructed to promptly reflect the vested awards in your E*Trade account.

(i) $41,560.92 representing payments equal to the aggregate cost of COBRA continuation coverage in respect of medical, vision and dental coverage for you and your eligible dependents for eighteen (18) months following the Separation Date, and (ii) $5,000 in respect of your financial planning allowance, in each case paid in a lump sum within ten (10) days following the Release Effective Date.

Continued use of Clarks Summit office for remainder of the current lease (but in no event longer than 6 months), subject to Rite Aid’s existing obligations to pay rent. You agree to reimburse the Company for any incremental costs or expenses due to your use during the remaining term and to abide by any notice requirements in the lease (which shall promptly be provided to the Company if received by or given by you).

$68,750 representing payment of thirty (30) days’ Base Salary in lieu of the notice period provided in the Employment Agreement, payable in a lump sum as soon as practicable following the Separation Date in accordance with the Company’s regular payroll schedule.

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

Filed on:	7/6/22
For Period end:	5/28/22
	4/13/22
	3/7/22
	10/2/19	8-K
		List all Filings

6 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/18/23  Rite Aid Corp.                    10-Q        9/02/23   88:12M                                    Toppan Merrill Bridge/FA
 7/11/23  Rite Aid Corp.                    10-Q        6/03/23   79:9.5M                                   Toppan Merrill Bridge/FA
 5/01/23  Rite Aid Corp.                    10-K        3/04/23  131:22M                                    Toppan Merrill Bridge/FA
 1/04/23  Rite Aid Corp.                    10-Q       11/26/22   92:13M                                    Toppan Merrill Bridge/FA
10/05/22  Rite Aid Corp.                    10-Q        8/27/22   89:12M                                    Toppan Merrill Bridge/FA
 7/27/22  Rite Aid Corp.                    S-8         7/27/22    4:93K                                    Toppan Merrill/FA

30 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/24/22  Rite Aid Corp.                    8-K:1,9     1/24/22   11:1.1M                                   Toppan Merrill/FA
10/05/21  Rite Aid Corp.                    10-Q        8/28/21   97:13M                                    Toppan Merrill Bridge/FA
 8/23/21  Rite Aid Corp.                    8-K:1,9     8/20/21   11:2M                                     Toppan Merrill/FA
 8/13/21  Rite Aid Corp.                    8-K:1,9     8/12/21   11:1M                                     Toppan Merrill/FA
 5/20/21  Rite Aid Corp.                    DEF 14A     7/07/21    1:11M                                    Toppan Merrill/FA
 4/27/21  Rite Aid Corp.                    10-K        2/27/21  137:23M                                    Toppan Merrill Bridge/FA
10/06/20  Rite Aid Corp.                    10-Q        8/29/20   90:12M                                    Toppan Merrill Bridge/FA
 7/27/20  Rite Aid Corp.                    8-K:1,2,9   7/27/20   12:1.2M                                   Toppan Merrill/FA
 7/08/20  Rite Aid Corp.                    8-K:5,9     7/08/20   12:308K                                   Toppan Merrill/FA
 4/27/20  Rite Aid Corp.                    10-K        2/29/20  145:29M                                    Toppan Merrill Bridge/FA
 4/17/20  Rite Aid Corp.                    8-K:5,9     4/15/20   11:467K                                   Toppan Merrill/FA
 2/05/20  Rite Aid Corp.                    8-K:1,2,8,9 2/05/20   12:1.1M                                   Toppan Merrill/FA
 1/07/20  Rite Aid Corp.                    8-K:1,8,9   1/06/20   12:396K                                   Toppan Merrill/FA
10/03/19  Rite Aid Corp.                    8-K:5,7,9  10/02/19    5:309K                                   Toppan Merrill/FA
 8/12/19  Rite Aid Corp.                    8-K:5,7,9   8/06/19    4:262K                                   Toppan Merrill/FA
 7/11/19  Rite Aid Corp.                    10-Q        6/01/19   94:15M                                    Toppan Merrill/FA
 4/18/19  Rite Aid Corp.                    8-K:3,5,9   4/18/19    2:36K                                    Toppan Merrill/FA
12/20/18  Rite Aid Corp.                    8-K:1,2,9  12/20/18    2:1.4M                                   Toppan Merrill/FA
 9/19/17  Rite Aid Corp.                    8-K:1,8,9   9/18/17    4:1M                                     Toppan Merrill/FA
 1/06/16  Rite Aid Corp.                    10-Q       11/28/15   75:10M                                    Toppan Merrill/FA
 6/23/14  Rite Aid Corp.                    8-K:5,9     6/19/14    2:226K                                   Toppan Merrill/FA
 4/23/13  Rite Aid Corp.                    10-K        3/02/13   97:13M                                    Toppan Merrill-FA
 6/25/12  Rite Aid Corp.                    8-K:5,9     6/21/12    2:239K                                   Toppan Merrill/FA
 5/15/12  Rite Aid Corp.                    8-K:1,2,8,9 5/14/12    5:396K                                   Toppan Merrill/FA
 2/24/12  Rite Aid Corp.                    8-K:5,9     2/17/12    2:49K                                    Skadden/FA
10/07/10  Rite Aid Corp.                    10-Q        8/28/10   34:2.6M                                   Toppan Merrill-FA
 6/25/10  Rite Aid Corp.                    8-K:5,9     6/23/10    2:255K                                   Skadden Arps Sla… LLP/FA
 6/11/09  Rite Aid Corp.                    8-K:1,2,8,9 6/05/09    7:2.5M                                   Skadden/FA
 2/07/00  Rite Aid Corp.                    8-K:5,7     1/26/00    6:42K                                    Skadden Arps Sla… LLP/FA
 3/19/99  Rite Aid Corp.                    S-4                   10:412K                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0001558370-22-010556 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)